Is BPC-157 FDA-approved?

By The Docket DeskResearched & sourcedUpdated 18 Jun 2026

The short answer

No. BPC-157 has not been approved as a drug by the FDA. Approval requires full clinical trials and a New Drug Application; BPC-157 has neither. Being removed from Category 2 in April 2026 changed its compounding status, not its approval status.

FDA approvalNot approved

Compounding statusRemoved from Category 2 (Apr 2026, nominations withdrawn) · not on Category 1 — compounding not authorized

Under FDA reviewPCAC · July 23, 2026

Use under reviewUlcerative colitis

Earliest pharmacy accessLate 2026–Q1 2027 (if cleared)

Approved vs compoundable vs “research-use” — the distinction that matters

An FDA-approved drug has cleared full clinical trials. A compoundable substance is one a licensed pharmacy may prepare to prescription, even without full approval, if it sits on the 503A Category 1 list. As of April 2026 BPC-157 was removed from Category 2 because the original nominations were withdrawn — but it was not moved to Category 1, so compounding is still not authorized and it is not covered by FDA enforcement discretion. Products labeled “for research use only” are not authorized for human use. This page does not provide sourcing, dosing, or preparation guidance.

What “not FDA-approved” means here

EVIDENCE GRADE · PRECLINICAL · MINIMAL HUMAN DATA

Human evidence is minimal. A 2025 systematic review of orthopedic and sports-medicine use (Vasireddi et al., PMID 40756949) identified 36 studies — 35 preclinical and only one clinical. The main human dataset is a small, uncontrolled retrospective review of about 16 knee-pain patients. A Phase II placebo-controlled hamstring-strain trial (NCT07437547) is recruiting in 2026 with no results yet; an earlier oral Phase I (NCT02637284) studied healthy volunteers. The FDA placed BPC-157 in Category 2 in 2023, citing concerns including immunogenicity, peptide-related impurities, and insufficient human data.

Will BPC-157 become legal in 2026?+

Not automatically. The committee meets July 23, 2026; a favorable vote is a recommendation only — the FDA must then issue a final rule, which typically takes months. Realistic legal compounded access is late 2026 to Q1 2027, and only if both steps go through.

Is “research-grade” BPC-157 the same as a medicine?+

No. Material sold “for research use only” is not made or tested to pharmaceutical standards, is not authorized for human use, and carries no guarantee of identity, purity or sterility. This site does not link to or evaluate these sellers.

Primary sources: 2025 review: PMID 40756949 · trials: ClinicalTrials.gov NCT07437547, NCT02637284 · FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.

Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. BPC-157 is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.